Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
IRVINE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ:NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study. This prospective, global, multi-center randomized controlled trial (“RCT”) compares the outcomes of intermediate-risk acute pulmonary embolism (“PE”) patients treated with the FlowTriever® System against those treated with traditional anticoagulation therapy alone. The first patient was enrolled by Dr. William H. Matthai, Jr., Director of Clinical Cardiology Research and Professor of Clinical Medicine (Cardiovascular Medicine) at Penn Presbyterian Medical Center at the University of Pennsylvania.
Related news for (NARI)
- Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
- Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
- Inari Medical Announces Joint Venture in Greater China
- inari medical reports third quarter 2024 financial results
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance